MK-0954E Study in Participants With Hypertension (MK-0954E-357)

• ClinicalTrials.gov Identifier: NCT01302691
• Recruitment Status: Completed
• First Posted: February 24, 2011
• Results First Posted: January 27, 2017
• Last Update Posted: March 15, 2019
• Sponsor: Merck Sharp & Dohme Corp.
• Information provided by (Responsible Party): Merck Sharp & Dohme Corp.

Study Description

Brief Summary:

This study is being done to evaluate the efficacy, safety, and tolerability of losartan potassium 50 mg (L50) + hydrochlorothiazide 12.5 mg (H12.5) + amlodipine besylate 5 mg (A5) (MK-0954E). The primary hypothesis is that L50/H12.5/A5 is more effective in lowering mean trough sitting diastolic blood pressure (SiDBP) after 8 weeks of treatment compared to L50+A5 in Japanese participants with essential hypertension who are not adequately controlled following an 8-week treatment with filter period study drug (L50+A5).

Condition or disease	Intervention/treatment	Phase
Hypertension	Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E); Drug: Losartan potassium; Drug: Amlodipine besylate; Drug: Placebo to MK-0954E; Drug: Placebo to losartan potassium; Drug: Placebo to amlodipine besylate	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 327 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration
• Actual Study Start Date: January 1, 2011
• Actual Primary Completion Date: April 1, 2012
• Actual Study Completion Date: April 1, 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: L50/H12.5/A5; Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.	Drug: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E); One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.; Drug: Placebo to losartan potassium; One tablet, containing placebo, orally, once daily, for 8 weeks.; Drug: Placebo to amlodipine besylate; One capsule, containing placebo, orally, once daily, for 8 weeks.
Active Comparator: L50 + A5; Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.	Drug: Losartan potassium; One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.; Drug: Amlodipine besylate; One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.; Drug: Placebo to MK-0954E; One tablet, containing placebo, orally, once daily, for 8 weeks.

Outcome Measures

Primary Outcome Measures :

1. Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) [ Time Frame: Baseline and Week 8 ]
   Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.
2. Percentage of Participants Who Experience ≥1 Adverse Event (AE) [ Time Frame: up to 14 days after last dose of study drug (up to 10 weeks) ]
   An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received.
3. Percentage of Participants Who Experience ≥1 Drug-related AE [ Time Frame: up to 14 days after last dose of study drug (up to 10 weeks) ]
   An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received.
4. Percentage of Participants Who Experience ≥1 Serious Adverse Event (SAE) [ Time Frame: up to 14 days after last dose of study drug (up to 10 weeks) ]
   An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received.
5. Percentage of Participants Who Experience ≥1 Drug-related SAE [ Time Frame: up to 14 days after last dose of study drug (up to 10 weeks) ]
   An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received
6. Percentage of Participants Who Had Study Drug Stopped Due to an AE [ Time Frame: up to 8 weeks ]
   An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm

Secondary Outcome Measures :

1. Change in Mean Trough Sitting Systolic Blood Pressure (SiSBP) [ Time Frame: Baseline and Week 8 ]
   Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm.

Eligibility Criteria

• Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion criteria

• Participant has a diagnosis of essential hypertension.
• Participant is being treated with single or dual treatment for hypertension and will be able to discontinue the prior antihypertensive medication.
• Participant has a mean trough SiDBP of ≥ 90 mmHg and < 110 mmHg.
• Participant has a mean trough SiSBP of ≥ 140 mmHg and < 200 mmHg.
• Participant has no clinically significant abnormality at screening visit.

Exclusion criteria

• Participant is currently taking > 2 antihypertensive medications.
• Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug, and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines).
• Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence.
• Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1).
• Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.

Contacts and Locations

Sponsors and Collaborators

Merck Sharp & Dohme Corp.

Investigators

• Study Director: Medical Director; Merck Sharp & Dohme Corp.

More Information

Publications of Results:

Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. Clin Exp Hypertens. 2015;37(3):260-6. doi: 10.3109/10641963.2014.954712. Epub 2014 Oct 1.

Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. Hypertens Res. 2015 May;38(5):329-35. doi: 10.1038/hr.2015.3. Epub 2015 Feb 26.

• Responsible Party: Merck Sharp & Dohme Corp.
• ClinicalTrials.gov Identifier: NCT01302691
• Other Study ID Numbers: 0954E-357
• First Posted: February 24, 2011
• Results First Posted: January 27, 2017
• Last Update Posted: March 15, 2019
• Last Verified: February 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
• URL: http://engagezone.msd.com/ds_documentation.php

Keywords provided by Merck Sharp & Dohme Corp.:

Essential hypertension; Uncontrolled hypertension; Antihypertensive agents; Blood pressure

Additional relevant MeSH terms:

Hypertension; Essential Hypertension; Vascular Diseases; Cardiovascular Diseases; Losartan; Amlodipine; Hydrochlorothiazide; Antihypertensive Agents; Calcium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs; Vasodilator Agents; Anti-Arrhythmia Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Diuretics; Natriuretic Agents; Sodium Chloride Symporter Inhibitors